DEC 0 3 5003 82

TRADE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) U.S. PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ATTY. DOCKET NO.	SER. NO.
00711 CIP	10/612,192
Applicant: PAL et al.	
FILING DATE	GROUP
July 2, 2003	Unassigned

(37 CFR 1.98(b))

U.S. PATENT DOCUMENTS

Examiner Initial	Cite No. ¹	Patent Number	Issue Date	Patentee	Class/ Subclass	Filing Date
 .						
						(
			.			
						,

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATIONS

Examiner Initial	Document Number	Publication Date	Country or Patent Office	Class/ Subclass	Translation Yes/No
BP	EP 0385909	09/05/1990	European Convention		
	WO 9205799	04/16/1992	PCT	•	
			:		

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial	Cite No. ¹	
BP		Allan, J.S. et al., "Major Glycoprotein Antigens That Induce Antibodies in AIDS Patients are Encoded by HTLV-III", Science, 228:1091-1094 (1985).
BP		Celada, F. et al., "Antibody Raised Against Soluble CD-4rgp 120 Complex Recognizes the CD4 Moiety and Blocks Membrane Fusion Without Inhibiting CD4-gp120 Binding", J. Exp. Med., 172:1443-1150 (1990).
ВР		Chamov, S.M. et al., "Conjugation of Soluble CD4 without Loss of Biological Activity via a Novel Carbohydrate Directed Cross-Linking Reagent", Journal of Biological Chemistry, 267 (22): 15916-15922

2003	[4	
<u> </u>		(1992).
EMARY	BP	Chanh, T.C. et al., "Induction of Anti-HIV Neutralizing Antibodies by Synthetic Peptides", EMBO J, 5:3065-3071 (1986).
		Cohen, J., "Jitters Jeopardizing Aids Vaccine Trials", Science, 262:980-981 (1993).
		Dalgleish, A.G. et al., "The CD4 (T4) Antigen is an Essential Component of the Receptor for the AIDS Retrovirus:, Nature, 312:763-767, 1984.
		Dolin et al., "The Safety and Innumogenicity of Human Immunodeficiency Virus Type 1 (HIV-1) Recombinant gp160 Candidate Vaccine in Humans", Ann Intern Med, 114:119-27 (1991).
		Dowd, C.S. et al., "β-Turn Phe in HIV-1 Env Binding Site of CD4 and CD4 Mimetic Miniprotein Enhances ENV Binding Affinity But Is Not Required for Activation of Co-Receptor/17b Site
		Edelman et al., International Review of Immunology, 7:151-66 (1990).
		Ezekowitz, R.A. et al., "A Human Serum Mannose-Binding Protein Inhibits In Vitro Infection by the Human Immunodeficiency Virus", J. Exp. Med., 169:185-196 (1989).
		Gattegno, L. et al., "Lectin-Carbohydrate Interactions and Infectivity of Human Immunodeficiency Virus Type 1 (HIV-1)", AIDS Res. Hum. Retroviruses, 8:27-37 (1992).
		Gershoni, J.M. et al., "HIV Binding to its Receptor Creates Specific Epitopes for the CD4/gp120 Complex", FASEB Journal, 7:12, 1185-1187 (Sept. 1993).
		Geyer, H. et al., "Carbohydrates of Human Immunodeficiency Virus Structures of Oligosaccharides Linked to the Envelope Glycoprotein 120", J. Biol. Chem., 263:11760—11767 (1988).
		Grewe, C. et al., "HIV: Early Virus-Cell Interactions", J. Acq. Immune Def. Synd., 3:965-974 (1990).
		Harlow et al., "Antibodies, A Laboratory Manual", Cold Spring Harbor Laboratory, (1988).
		Hart, T.K. et al., "Binding of Soluble CD4 Proteins to Human Immunodeficiency Virus Type 1 and Infected Cells Induces Release of Envelope Glycoprotein gp120", Proc. Natl. Acad. Sci. USA, 88:2189-2193 (1991).
		Haynes, B.F. et al., "Scientific and Social Issues of Human Immunodeficiency Virus Vaccine Development", Science, 260:1279-1286, (May 1993).
	V	Ho, D.D. et al., "Conformational Epitope on gp120 important in CD4 Binding and Human Immunodeficiency Virus Type 1 Neutralization

DEC. a 2 2	밁	. DEPARTM	ENT OF COMME	Sheet 3 of 5 PATENT & TRADEN
TRADEMARY	5/	BP		Identified by a Human Monoclonal Antibody", J. Virol., 65:489-493 (1991).
			·	Ho, D.D. et al., "Second Conserved Domain of gp120 is Important for HIV Infectivity and Antibody Neutralization", Science, 239:1021-1023 (1988).
				Kahn, J.O. et al., "The Safety and Pharmacokinetics of Recombinant Soluble CD4 (rCD4) in Subjects with the Acquired Immunodeficiency Syndrom (AIDS) and AIDS-Related Complex", A Phase 1 Study-Ann. Inter. Med., 112:254-261 (1990).
				Kang, C. et al., FASEB Journal, 8:5: Abstract 5567 (April 1994).
				Larkin, M. et al., "Oligosaccharide-Mediated Interactions of the Envelope Glycoprotein gp120 of HIV-1 that are Independent of CD4 Recognition", AIDS, 3:793-798 (1989).
				Masuda, T. et al., "Generation of Neutralization-Resistant HIV-1 In Vitro Due to Amino Acid Interchanges of Third Hypervariable env. Region", J. Immunol., 145:3240-3246 (1990).
				McDougal, J.S et al., "Binding of HTLV-II/LAV to T4+T Cells By a Complex of the 110K Viral Protein and the T4 Molecule", Science, 231:382-385 (1986).
				Mizuochi, T. et al., "Diversity of Oligosaccharide Structures on the Envelope Glycoprotein gp120 of Human Immunodeficiency Virus I from the Lympoblastoid Cell Line H9, Presence of Complex-Type Oligosaccharides with Bisecting N-acetylglucosamine Residues", J. Biol. Chem., 265:1139-1142 (1990).
			1	Moore, J. P. et al., "Dissociation of gp120 from HIV-1 Virions Induced Soluble CD4", Science, 250:1139-1142 (1990).
				Ohno, T. et al., "A Broadly Neutralizing Monoclonal Antibody that Recognizes that V3 Region of Human Immunodeficiency Virus Type 1 Glycoprotein gp120", Proc. Natl. Acad. Sci. USA, 88:10726-10729, (1991).
			1	Pal, R. et al., "Characterization of a Neutralizing Monoclonal Antibody to the External Glycoprotein of HIV-1", Intervirology, in Press.
				Pal, R. et al., "Conformational Perturbation of the Envelope Glycoprotein gp120 of Human Immunodeficiency Virus Type 1 by Soluble CD4 and the Lection Succinyl Con A", Virology, 194:833-837 (1993).
				Putney, S., "How Antibodies Block HIV Infection: Pathes to an AIDS Vaccine", TIBS, 17:191-196 (1992).
	1			Putney, S. et al., "Structural and Functional Features of the HIV Envelope Glycoprotein and Considerations for Vaccine Development", Biotechnology, 14:81-110 (1990).

45		
2003 F	BP	Robert-Guroff, M., "HIV-Neutralizing Antibodies: Epitope Identification and Significance for Future Vaccine", Int. Rev. Immunology, 7:15-30 (1990).
DEM.		Robey, W.G. et al., "Prospect for Prevention of Human Immunodeficiency Virus Infection: Purified 120-kDA Envelope Glycoprotein Induces Neutralizing Antibody", Proc. Natl. Acad. Sci. USA, 83:7023-7027 (Sept. 1986).
		Robinson, W.E. Jr. et al., "Evidence That Mannos yl Residues are Involved in Human Immunodeficiency Virus Type I (HIV-1) Pathogenesis" AIDS Res. Hum. Retroviruses, 3:265-282 (1987).
		Sattentau, Q.J. et al., "Conformational Changes Induced in the Human Immunodeficiency Virus Envelope Glycoprotein by Soluble CD4 Binding", J. Exp. Med., 174:407-415 (Aug. 1991).
		Schooley, R.T. et al., "Recombinant Soluble CD4 Therapy in Patients with the Acquired Immunodeficiency Syndrome (AIDS) and AIDS-Related Complex A Phase I-II Escalating Dosage Trial", Ann. Int. Med., 112:247-253 (1990).
		Sun, N.C. et al., "Generation and Characterization of Monoclonal Antibodies to the Putative CD4-Binding Domain of Human Immunodeficiency Virus Type I gp120 Envelope Glycoprotein", J. Virology, 63:3579-3585 (1992).
	,	Thali, M. et al., "Discontinuous Conserved Neutralization of Epitopes Overlapping the CD4 Binding Region of Human Immunodeficiency Virus Type 1 gp120 Envelope Glycoprotein", J. Virology, 66:5636-5641 (1992).
		Veronese, F.D. et al., "Characterization of gp41 as the Transmembrane Protein Coded by the HTLV-III/LAV Envelope Gene", Science, 229:1402-1405, (1985).
		Veronese, F.D. et al., "Delineation of Immunoreactive Conserved Regions in the External Glycoprotein of the Human Immunodeficiency Virus Type 1", AIDS Res. Human Retroviruses, 8:1125-1132, (1992).
		Watanabe, M. et al., "Chimpanzees Immunized with Recombinant Soluble CD4 Develop Anti-Self CD4 Antibody Responses with Anti-Human Immunodeficiency Virus Activity", Proc. Natl. Acad. Sci. USA, 89:5103-5107 (1992).
•		Watanabe, M. et al., "Soluble Human CD4 Elicits an Antibody Response in Rhesus Monkeys that Inhibits Simian Immunodeficiency Virus Replication", Proc. Natl. Acad. Sci. USA, 88:120-124 (1991).

PATENT & TRADEMARK OFFICE

Sheet 5 of 5

U.S. DEPARTMENT OF COMMERCE

DEC 0 3 2003

/Bo Peng/
DATE CONSIDERED
11/09/2006

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.